11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum

11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum

Dermatomyositis: Clinical Spectrum and Hallmark Morphology

Dermatomyositis (DM) is a systemic idiopathic inflammatory myopathy displaying prominent, distinctive cutaneous features. It affects both adults (bimodal peak at 45–60 years) and children (juvenile DM, peak at 5–14 years). While classical dermatomyositis couples progressive, symmetric proximal skeletal muscle weakness (shoulder and pelvic girdles) with cutaneous inflammation, approximately 20% of patients present with Clinically Amyopathic Dermatomyositis (CADM / dermatomyositis siné myositis), defined as hallmark cutaneous disease persisting for >=6 months in the complete absence of clinical muscle weakness or elevated muscle enzymes (creatine kinase, aldolase, LDH, AST/ALT).

Pathognomonic Cutaneous Signs

1. Heliotrope Rash: A confluent, violaceous-to-dusky erythematous eruption localized symmetrically over the upper eyelids and periorbital tissue, accompanied by periorbital edema. The name derives from the violaceous petals of the Heliotropium flower. It is frequently accompanied by fine telangiectasias and may involve the lower eyelids.
2. Gottron's Papules: Violaceous, flat-topped, lichenoid or polygonal papules symmetrically overlying the dorsal bony prominences of the metacarpophalangeal (MCP), proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints. Over time, lesions develop central atrophy, porcelain-white scale, telangiectasia, or hypopigmentation. High-Yield Contrast: Lupus erythematosus classically involves the skin between the joints (interphalangeal spaces), whereas Gottron's papules reside directly over the joint surfaces.
3. Gottron's Sign: Macular, violaceous, symmetric erythema (with or without scaling and atrophy) overlying the extensor surfaces of other joints, specifically the elbows, patellae, and medial malleoli.

┌────────────────────────────────────────────────────────────────────────────────────────┐
│                     Comparative Anatomy: Hands in DM vs Lupus                          │
├────────────────────────────────────────────────────────────────────────────────────────┤
│  Dermatomyositis (Gottron's Papules):                                                  │
│    Erythematous/violaceous papules DIRECTLY OVER the MCP, PIP, and DIP joint surfaces. │
│                                                                                        │
│  Systemic Lupus Erythematosus (ACLE Exanthem):                                         │
│    Erythematous macular eruption IN BETWEEN the joints (sparing the articular skin).   │
└────────────────────────────────────────────────────────────────────────────────────────┘

Characteristic & Secondary Cutaneous Features

• Shawl Sign: Confluent, poikilodermatous (erythema, hypopigmentation, hyperpigmentation, atrophy, telangiectasia) violaceous erythema distributed over the posterior neck, upper back, and shoulders.
• V-Neck Sign: Confluent erythema and poikiloderma across the anterior lower neck and upper presternal chest, corresponding to the area exposed by an open-collared shirt.
• Holster Sign: Violaceous macules or poikilodermatous patches over the lateral aspects of the thighs and hips, immediately inferior to the greater trochanters.
• Periungual Telangiectasia & Keining's Sign: Prominent cuticular hypertrophy, hyperkeratosis, cuticular microhemorrhages, and ragged cuticles accompanied by dilated, tortuous, thrombosed periungual capillary loops (Keining's sign).
• Mechanic's Hands: Symmetrical, non-pruritic, hyperkeratotic, fissured, scaling, and hyperpigmented roughening along the palmar and radial margins of the index fingers and thumbs, resembling the hands of a manual laborer. Highly characteristic of the Antisynthetase Syndrome.
• Calcinosis Cutis: Dystrophic, rock-hard subcutaneous and fascial calcifications (insoluble calcium hydroxyapatite deposition). Uncommon in adults (<10%), but present in up to 40% to 50% of Juvenile Dermatomyositis (JDM). Nodules frequently ulcerate, extruding chalky white calcium paste, and can induce chronic non-healing ulcers, severe joint contractures, and secondary sepsis.
• Cutaneous Ulcerations: Deep, punched-out, painful ulcers occurring on the digital pulps or directly overlying Gottron's papules, representing microvascular ischemic infarction. Strongly linked to anti-MDA5 autoantibodies.

---

Myositis-Specific Antibodies (MSAs) & Clinical Phenotyping

Myositis-specific antibodies (MSAs) are mutually exclusive autoantibodies directed against intracellular antigens that dictate distinctive clinical phenotypes, internal organ involvement, and malignancy risks.

Paraneoplastic Dermatomyositis and Cancer Screening Protocol

Adult dermatomyositis is a classic paraneoplastic syndrome; approximately 25% to 30% of adult DM cases are driven by an underlying malignancy. The relative risk of cancer is highest in the first year following DM onset, remaining significantly elevated for 3 to 5 years.

• Associated Malignancies: Ovarian carcinoma (highest relative risk, ~10-fold increase), lung adenocarcinoma, breast carcinoma, gastrointestinal malignancies (colorectal, gastric, pancreatic), nasopharyngeal carcinoma (especially in Southeast Asian populations), and non-Hodgkin lymphoma.
• High-Risk Biomarkers: Elderly onset (>50 years), rapid onset of cutaneous necrosis, refractory cutaneous disease, and positivity for anti-TIF1-gamma or anti-NXP2 autoantibodies.
• Mandatory European Adult Screening Protocol at Diagnosis:
  1. Comprehensive History & Physical Examination: Complete skin inspection, lymph node palpation, breast examination, digital rectal exam, and pelvic/bimanual examination.
  2. Laboratory Panel: Complete blood count, liver/renal profiles, serum protein electrophoresis, urine analysis, and serum tumor markers (CA-125, CA 19-9, CEA, PSA).
  3. Cross-Sectional Imaging: Contrast-enhanced CT scan of the chest, abdomen, and pelvis (or whole-body 18F-FDG PET-CT scan).
  4. Targeted Organ Screening: Bilateral mammography and transvaginal/pelvic ultrasound in women; age-appropriate colonoscopy; nasopharyngoscopy in Asian patients.
  5. Surveillance Horizon: Serial clinical surveillance and repeat cross-sectional imaging annually or bi-annually for a minimum of 3 years post-diagnosis.

---

Systemic Sclerosis (SSc): Limited vs Diffuse Spectrum

Systemic Sclerosis (SSc) is a multisystem autoimmune connective tissue disease driven by a pathophysiologic triad:

1. Severe microvascular endothelial injury.
2. Widespread immune activation and autoantibody production.
3. Uncontrolled fibroblast activation resulting in excessive synthesis and deposition of extracellular matrix (Type I and Type III collagen), causing tissue fibrosis.

                                    ┌────────────────────────────────────────────────────────┐
                                    │              Systemic Sclerosis Spectrum               │
                                    └───────────────────────────┬────────────────────────────┘
                                                                │
                                ┌───────────────────────────────┴───────────────────────────────┐
                                │                                                               │
                ┌───────────────▼───────────────┐                               ┌───────────────▼───────────────┐
                │    Limited Cutaneous (lcSSc)  │                               │    Diffuse Cutaneous (dcSSc)  │
                └───────────────┬───────────────┘                               └───────────────┬───────────────┘
                                │                                                               │
                                ├─ Acral skin thickening (hands/face)                           ├─ Rapid proximal skin thickening (trunk/arms)
                                ├─ Raynaud precedes skin signs by years                         ├─ Raynaud onset synchronous with skin signs
                                ├─ CREST syndrome                                               ├─ Early visceral fibrosis (Severe ILD)
                                ├─ Anti-Centromere Antibodies (ACA)                             ├─ Anti-Scl-70 / Anti-RNA Polymerase III
                                └─ Late Pulmonary Arterial Hypertension                         └─ High risk of Scleroderma Renal Crisis (SRC)

Classification Architecture: lcSSc vs dcSSc

1. Limited Cutaneous Systemic Sclerosis (lcSSc)

• Cutaneous Extent: Skin sclerosis is strictly confined to the distal extremities (distal to the elbows and knees) and the face/neck, completely sparing the trunk and proximal limbs.
• Vascular Phenotype: Raynaud phenomenon precedes cutaneous thickening by years or decades. Progression is indolent.
• CREST Syndrome: The classic acronym describing the lcSSc phenotype:
  • Calcinosis cutis (subcutaneous periarticular nodules).
  • Raynaud phenomenon (triphasic digital ischemia).
  • Esophageal dysmotility (lower esophageal sphincter incompetence, severe gastroesophageal reflux, dysphagia).
  • Sclerodactyly (tapered, indurated, shiny fingers with loss of normal skin folds).
  • Telangiectasia (mat-like, dilated, polygonal capillary clusters on the face, lips, hands, and oral mucosa).
• Autoantibody Hallmark: Anti-Centromere Antibodies (ACA / CENP-A/B) in 60% to 80%.
• Late Life-Threatening Complication: Pulmonary Arterial Hypertension (PAH) develops in 10% to 15% of lcSSc patients, typically after 10 to 15 years of disease. Characterized by pre-capillary pulmonary vascular remodeling. Requires mandatory annual screening with transthoracic echocardiography, pulmonary function tests (DLCO decline out of proportion to FVC), and serum NT-proBNP.

2. Diffuse Cutaneous Systemic Sclerosis (dcSSc)

• Cutaneous Extent: Rapidly progressive skin induration extending proximally above the elbows and knees, involving the chest, abdomen, and thighs.
• Vascular Phenotype: Raynaud phenomenon develops simultaneously with, or within months of, sudden inflammatory puffy hands and rapid skin tightness.
• Visceral Fibrotic Complications: Early, aggressive visceral involvement within the first 3 to 5 years:
  • Interstitial Lung Disease (ILD): Pulmonary fibrosis presenting with exertional dyspnea, dry bibasilar crackles, restrictive spirometry (reduced FVC), and subpleural ground-glass/reticulation on High-Resolution CT (HRCT).
  • Gastrointestinal Dysmotility: Gastric antral vascular ectasia ("watermelon stomach"), small-bowel bacterial overgrowth (SIBO), and pseudo-obstruction.
  • Myocardial Fibrosis: Conduction blocks, diastolic dysfunction, and arrhythmias.
• Autoantibody Biomarkers in dcSSc:
  • Anti-Topoisomerase I (Anti-Scl-70): Present in 30% of dcSSc; serves as a potent predictor of severe, rapidly progressive fibrosing Interstitial Lung Disease (ILD) and reduced overall survival.
  • Anti-RNA Polymerase III: Present in 15% to 20% of dcSSc; tightly associated with rapid, aggressive skin sclerosis, tendon friction rubs, a recognized synchronous paraneoplastic malignancy risk, and an extraordinarily high risk for Scleroderma Renal Crisis (SRC).

Scleroderma Renal Crisis (SRC): Corticosteroid Avoidance & Emergency Management

Scleroderma renal crisis occurs in up to 10% to 15% of dcSSc patients (especially those harboring anti-RNA polymerase III antibodies).

• Pathophysiology & Triggers: Sudden, catastrophic renal arcuate and interlobular artery obliterative vasculopathy with intimal proliferation ("onion-skinning"), triggering severe cortical ischemia and hyperreninism.
• THE CRITICAL CLINICAL TRAP: Systemic Corticosteroids: High-dose systemic corticosteroids (prednisone >15 mg/day equivalent) are a major established iatrogenic trigger for precipitating SRC. Corticosteroids must be avoided or kept at the absolute minimum necessary in patients with early dcSSc!
• Clinical Presentation: Abrupt-onset malignant hypertension (typically >180/110 mmHg, though 10% can be normotensive), headache, encephalopathy, visual disturbances, oliguric acute renal failure, and microangiopathic hemolytic anemia (MAHA with schistocytes and thrombocytopenia).
• First-Line Emergency Therapy: Immediate hospitalization and rapid initiation of Angiotensin-Converting Enzyme (ACE) Inhibitors—specifically titrated short-acting Captopril (starting at 6.25–12.5 mg every 8 hours and titrating aggressively). ACE inhibitors specifically reverse renin-angiotensin-aldosterone vasoconstriction, rescuing renal hemodynamics and reducing mortality from >90% to <30%. Blood pressure should not be dropped precipitously, aiming for a reduction of 20 mmHg systolic per day until normalization.

---

Nailfold Capillaroscopy (NFC) in Raynaud & Scleroderma

Nailfold videocapillaroscopy is an indispensable, non-invasive European diagnostic standard for evaluating Raynaud phenomenon, allowing differentiation of primary Raynaud (normal parallel hairpin capillary loops) from secondary Raynaud driven by Systemic Sclerosis spectrum disorders.

                                    ┌────────────────────────────────────────────────────────┐
                                    │      Cutolo Nailfold Capillaroscopy Classification     │
                                    └───────────────────────────┬────────────────────────────┘
                                                                │
                ┌───────────────────────────────────────────────┼───────────────────────────────────────────────┐
                │                                               │                                               │
┌───────────────▼───────────────┐               ┌───────────────▼───────────────┐               ┌───────────────▼───────────────┐
│         Early Pattern         │               │        Active Pattern         │               │         Late Pattern          │
└───────────────┬───────────────┘               └───────────────┬───────────────┘               └───────────────┬───────────────┘
                │                                               │                                               │
                ├─ Giant capillaries (>50 µm)                   ├─ Frequent giant capillaries                   ├─ Severe capillary loss (drop-out)
                ├─ Occasional microhemorrhages                  ├─ Frequent microhemorrhages                    ├─ Extensive avascular areas
                ├─ Preserved capillary architecture             ├─ Moderate capillary loss                      ├─ Neoangiogenesis (ramified/bushy loops)
                └─ NO significant capillary loss                └─ Mild architecture disorganisation            └─ Severe structural disorganisation

The Cutolo Capillaroscopic Classification Criteria

1. Early Pattern:
   • Few, scattered giant capillaries (homogeneous dilation >=50 micrometers).
   • Rare or isolated microhemorrhages.
   • Well-preserved capillary distribution and density (no significant capillary drop-out / avascular fields).
   • Normal architecture maintained.
2. Active Pattern:
   • Frequent, prominent giant capillaries.
   • Frequent microhemorrhages.
   • Moderate loss of capillaries (drop-out producing small avascular areas).
   • Mild disorganisation of the vascular array; mild capillary arborization.
3. Late Pattern:
   • Extensive avascular areas with severe, widespread capillary drop-out.
   • Complete or near-complete absence of giant capillaries (exhausted loops).
   • Severe capillary disorganisation with exuberant, aberrant neoangiogenesis featuring ramified, bushy, or branched capillary clusters.
   • Correlates with advanced internal organ fibrosis and elevated digital ischemic ulcer risk.

---

Localised Scleroderma (Morphoea)

Morphoea represents an inflammatory and sclerosing disease strictly limited to the skin, subcutaneous fat, and rarely underlying fascia, muscle, and bone. In stark contrast to systemic sclerosis, morphoea is defined by the absolute absence of sclerodactyly, Raynaud phenomenon, nailfold capillaroscopic abnormalities, or internal organ sclerosis. Patients exhibit normal life expectancy.

Clinical Subtypes (European Dermatology Forum Classification)

1. Plaque Morphoea (Circumscribed):
   • The most common adult form. Starts as an indurated, erythematous-to-violaceous plaque with an active expanding inflammatory border known as the "lilac ring".
   • As inflammation subsides, the center becomes sclerotic, waxy, ivory-white, or porcelain, with complete loss of hair follicles and eccrine sweating.
   • Over years, the plaque softens, burning out into a residual atrophic, hyperpigmented or hypopigmented macule.
2. Generalised Morphoea:
   • Defined by >=4 large indurated plaques (>=3 cm) involving >=2 distinct anatomical body sites (e.g., trunk and bilateral extremities).
   • Severe circumferential thoracic involvement can restrict respiratory chest wall expansion.
3. Linear Morphoea:
   • Most common subtype in children (paediatric morphoea).
   • Manifests as an indurated, band-like linear streak involving the dermis, panniculus, deep fascia, muscle, and periosteum. Predominantly affects extremities, crossing joint lines and inducing severe growth impairment, limb length discrepancies, muscle atrophy, and permanent joint flexion contractures.
4. Linear Morphoea of the Head and Face:
   • En Coup de Sabre (Frontoparietal Morphoea): Linear, depressed, ivory furrow resembling a saber cut extending vertically from the forehead into the parietal scalp, inducing permanent linear cicatricial alopecia and underlying bone depression.
   • Parry-Romberg Syndrome (Progressive Hemifacial Atrophy): Deep, extensive neurocutaneous atrophy affecting one half of the face, with progressive wasting of subcutaneous fat, facial musculature, cartilage, and bone, often with subtle or absent cutaneous sclerosis. Strongly associated with neurological complications (intractable seizures, migraines) and ophthalmological pathology (enophthalmos, uveitis).
5. Deep Morphoea & Eosinophilic Fasciitis (Shulman Syndrome):
   • Morphoea Profunda: Dense, woody sclerosis centered on deep subcutaneous fat and fascia.
   • Eosinophilic Fasciitis: Sudden-onset symmetrical, painful woody induration of the forearms and lower legs following strenuous physical exertion. Spares the hands and feet. Characteristic "groove sign" (linear indentation along the course of superficial veins when the limb is elevated). Hallmark: intense peripheral blood eosinophilia, hypergammaglobulinemia, and thickened, fibrotic deep fascia packed with lymphocytes, histiocytes, and eosinophils.

Therapeutic Principles for Morphoea

• Superficial, Limited Plaque Morphoea: Topical superpotent corticosteroids (European Class IV, e.g., clobetasol propionate) or topical calcineurin inhibitors (tacrolimus 0.1% ointment) applied to the active lilac border; topical calcipotriol.
• Widespread or Disfiguring Morphoea: Phototherapy using UVA-1 (340–400 nm)—specifically medium-dose (50 J/cm²) or high-dose (130 J/cm²) regimens. UVA-1 penetrates deeply into the reticular dermis, inducing matrix metalloproteinases (MMP-1, MMP-3) and downregulating TGF-beta.
• Rapidly Progressive, Deep, Linear, or Joint-Threatening Morphoea: Requires urgent systemic immunosuppression to prevent permanent orthopedic deformity:
  • Systemic Methotrexate (MTX): 15 mg/m²/week (or 0.3–0.5 mg/kg/week in children; 15–25 mg/week in adults) administered subcutaneously for at least 12 to 24 months.
  • Combination Pulsed Corticosteroids: Intravenous pulsed methylprednisolone (30 mg/kg/day, max 1,000 mg/day, for 3 consecutive days monthly for 3–6 months) or oral prednisolone (1 mg/kg/day tapered over 2–3 months) as an induction bridge until methotrexate achieves therapeutic tissue efficacy.